266 related articles for article (PubMed ID: 37589827)
1. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Le J; Talele S; Sarkaria JN; Elmquist WF
Pharm Res; 2023 Nov; 40(11):2731-2746. PubMed ID: 37589827
[TBL] [Abstract][Full Text] [Related]
2. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
3. Transporter-based delivery of anticancer drugs to the brain: improving brain penetration by minimizing drug efflux at the blood-brain barrier.
On NH; Miller DW
Curr Pharm Des; 2014; 20(10):1499-509. PubMed ID: 23789953
[TBL] [Abstract][Full Text] [Related]
4. Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
Cui Y; Lotz R; Rapp H; Klinder K; Himstedt A; Sauer A
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31718023
[TBL] [Abstract][Full Text] [Related]
5. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
Summerfield SG; Zhang Y; Liu H
J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
[TBL] [Abstract][Full Text] [Related]
6. Unbound Brain-to-Plasma Partition Coefficient, K
Loryan I; Reichel A; Feng B; Bundgaard C; Shaffer C; Kalvass C; Bednarczyk D; Morrison D; Lesuisse D; Hoppe E; Terstappen GC; Fischer H; Di L; Colclough N; Summerfield S; Buckley ST; Maurer TS; Fridén M
Pharm Res; 2022 Jul; 39(7):1321-1341. PubMed ID: 35411506
[TBL] [Abstract][Full Text] [Related]
7. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on Nanodelivery to the Brain: Prerequisites for Successful Brain Treatment.
Hu Y; Hammarlund-Udenaes M
Mol Pharm; 2020 Nov; 17(11):4029-4039. PubMed ID: 33064009
[TBL] [Abstract][Full Text] [Related]
9. Practical Application of Rodent Transporter Knockout Models to Assess Brain Penetration in Drug Discovery.
Eneberg E; Jones CR; Jensen T; Langthaler K; Bundgaard C
Drug Metab Bioanal Lett; 2022; 15(1):12-21. PubMed ID: 35196975
[TBL] [Abstract][Full Text] [Related]
10. Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma.
Zhang W; Vaubel RA; Oh JH; Mladek AC; Talele S; Zhang W; Waller KL; Burgenske DM; Sarkaria JN; Elmquist WF
Mol Cancer Ther; 2024 Jan; 23(1):47-55. PubMed ID: 37828724
[TBL] [Abstract][Full Text] [Related]
11. Revisiting atenolol as a low passive permeability marker.
Chen X; Slättengren T; de Lange ECM; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2017 Oct; 14(1):30. PubMed ID: 29089037
[TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics.
Ronaldson PT; Davis TP
Expert Opin Drug Deliv; 2024; 21(1):71-89. PubMed ID: 38217410
[TBL] [Abstract][Full Text] [Related]
13. Efflux Limits Tumor Drug Delivery Despite Disrupted BBB.
Griffith JI; Sarkaria JN; Elmquist WF
Trends Pharmacol Sci; 2021 Jun; 42(6):426-428. PubMed ID: 33736874
[TBL] [Abstract][Full Text] [Related]
14. Assessing extent of brain penetration in vivo (K
Langthaler K; Jones CR; Brodin B; Bundgaard C
Eur J Pharm Sci; 2023 Nov; 190():106554. PubMed ID: 37543065
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Aripiprazole Uptake Transporter in the Blood-Brain Barrier Model hCMEC/D3 Cells by Targeted siRNA Screening.
Kadoguchi M; Arakawa H; Honda R; Hotta K; Shirasaka Y; Deguchi Y; Tamai I
Pharm Res; 2022 Jul; 39(7):1549-1559. PubMed ID: 35314999
[TBL] [Abstract][Full Text] [Related]
16. The role of membrane transporters in drug delivery to brain tumors.
Nies AT
Cancer Lett; 2007 Aug; 254(1):11-29. PubMed ID: 17275180
[TBL] [Abstract][Full Text] [Related]
17. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
[TBL] [Abstract][Full Text] [Related]
18. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
19. A Computational Physics-based Approach to Predict Unbound Brain-to-Plasma Partition Coefficient, K
Lawrenz M; Svensson M; Kato M; Dingley KH; Chief Elk J; Nie Z; Zou Y; Kaplan Z; Lagiakos HR; Igawa H; Therrien E
J Chem Inf Model; 2023 Jun; 63(12):3786-3798. PubMed ID: 37267072
[TBL] [Abstract][Full Text] [Related]
20. Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies.
Yusof SR; Mohd Uzid M; Teh EH; Hanapi NA; Mohideen M; Mohamad Arshad AS; Mordi MN; Loryan I; Hammarlund-Udenaes M
Addict Biol; 2019 Sep; 24(5):935-945. PubMed ID: 30088322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
